 |
市场调查报告书
商品编码
1197715
神经介入设备市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)Neurointerventional Devices Market - Growth, Trends, and Forecasts (2023 - 2028) |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
在预测期内，神经介入设备市场的复合年增长率预计为 7.7%。
COVID-19 爆发将以多种方式影响神经介入设备市场，从需要限制重症监护病房 (ICU) 病床和通风场所，到推迟择期和/或复杂病例。 此外，分析表明，在大流行期间和之后，神经干预的管理存在很大差异。 例如，根据 Cardiovascular Revascularization Medicine 2022 年 7 月的一份报告，需要在血管介入领域进行更多研究，以确定因 COVID-19 大流行而停止的介入性血管试验的总体影响。假设是 然而，由于医疗机构的重新开放、COVID-19患者的减少以及COVID-19后血管介入的后续试验，预计市场将迅速復苏。
市场增长的主要驱动因素是患者人数的增加、产品开发和商业化的持续进行，以及神经血管治疗领域研究活动的增加。
神经介入设备由专注于中枢神经系统 (CNS) 领域的医疗保健专业人员使用。 它通常由神经放射学家、神经外科医生和寻求血管内方法治疗中枢神经系统血管疾病的神经学家进行。 受试者中与中枢神经系统相关的血管疾病的负担主要驱动设备的使用。 根据 2022 年 6 月更新的 WSO 数据，到今年年底，约有 1220 万人 (12,224,551) 将经历中风。 颅内动脉瘤，也称为脑动脉瘤或脑动脉瘤，是大脑中动脉壁的膨胀和薄弱区域。 2022 年 4 月更新的英国国家医疗服务体系 (NHS) 数据显示，脑动脉瘤的患病率可高达每 20 人中就有 1 人，而且脑动脉瘤会影响任何人，无论年龄大小。它会发生，但最常见见于40岁以上的人。 此外，根据 2022 年 1 月脑动脉瘤基金会的更新，估计有 650 万美国人患有未破裂的脑动脉瘤。 在美国，每年约有 30,000 人患有脑动脉瘤破裂。 每 18 分钟就有一个脑动脉瘤破裂。 随着越来越多的中枢神经和血管疾病患者来到医疗机构，对神经介入设备的需求预计会增长。
同样，新设备的开发和批准也将在研究期间推动市场的增长。 例如，2021 年 4 月，美敦力 (Medtronic) 的 Pipeline Flex Embolization Device 屏蔽技术获得美国 FDA 批准。 Pipeline Flex 栓塞装置可转移脑动脉瘤的血流。
在分析期间，这些因素充分促进了市场的增长。 然而，严格的法规和熟练的神经外科医生短缺是该市场增长的主要限制。
神经介入设备的市场趋势
预计在预测期内，缺血性中风部分将占市场的主要份额
缺血性中风的特征是大脑的一部分突然失去血液循环以及相关的神经功能恶化。 对该细分市场产生积极影响的关键因素包括缺血性中风发病率的增加以及市场上各个主要参与者的发展。
例如，根据 WSO 的 2022 年全球中风情况说明书，每年发生超过 760 万例新的缺血性中风。 在全球范围内，超过 62% 的中风是缺血性中风。 这表明每年需要使用神经介入设备进行适当的神经介入治疗的病例数都在显着增加。 因此，在预测期内，缺血性中风等血管疾病发病率的增加将推动神经介入设备市场的发展。
同样，在研究期间，用于缺血性中风的设备的最新发展推动了市场增长。 例如，2022 年 6 月，Rapid Medical 在 DISTALS 试验中招募了第一位患者。 这项研究是有史以来第一个 FDA 研究设备豁免（ IDE ），使用最小和最可调节的取栓设备 TIGERTRIEVER 13 测试机械取栓术在远端中风中的安全性和有效性。 这是一项考试。 神经介入设备的用途是巨大的，广泛的用途导致动脉疾病的矫正。 同样，2022年2月，微创神通有限公司（以下简称微创神通）自主研发的Neurohawk支架取栓器（以下简称Neurohawk）获得国家药监局上市许可。 Neurohawk是微创神通推出的治疗急性缺血性脑卒中的血栓支架取栓器。
因此，鑑于上述事实，预计研究市场在预测期内将会增长。
预计在预测期内北美将占据很大的市场份额
北美地区的贡献在美国是最高的，这是该地区在全球占据主导地位的一个因素。 由于许多地方拥有先进的医疗保健基础设施以及许多与医院有联繫的医疗设备製造商，北美主要推动了该市场的增长。
根据疾病预防控制中心 2022 年 4 月发布的数据，超过 795,000 名美国人中风。 每年，这些病例中会发现 610,000 例新病例。 大约 87% 的中风是缺血性中风，其中流向大脑的血液受阻。 因此，该地区中风患者数量的增加将增加对神经介入设备进行适当管理的需求，从而有助于预测期内市场的增长。
此外，新设备的批准和发布也将有助于市场增长。 例如，2022 年 2 月，CERENOVUS 推出了 EMBOGUARD，这是一种用于血管内治疗的下一代球囊引导导管，包括急性缺血性中风患者。 EMBOGUARD 球囊引导导管旨在通过在 MT 手术期间局部控制血流来优化血栓清除。 因此，每一个新设备的批准和发布都有助于该地区的市场增长。
因此，上述所有因素都有望在预测期内推动市场增长。
神经介入器械市场竞争者分析
神经介入设备市场竞争适中，由几家大型企业组成。 这些公司在通过神经介入设备治疗血管内疾病方面看到了持续的增长机会。 该领域的主要公司包括雅培、强生服务公司（CERENOVUS）、美敦力、史赛克、Penumbra, Inc.、MicroPort Scientific Corporation、Terumo Corporation 和 W. L. Gore & Associates, Inc.。
其他好处
- Excel 格式的市场预测 (ME) 表
- 三个月的分析师支持
内容
第一章介绍
- 研究假设和市场定义
- 调查范围
第二章研究方法论
第 3 章执行摘要
第四章市场动态
- 市场概览
- 市场驱动因素
- 增加目标患者的数量
- 持续的产品开发和商业化
- 激活神经血管治疗领域的研究活动
- 市场製约因素
- 严格监管
- 缺乏熟练的神经外科医生
- 波特的五力分析
- 新进入者的威胁
- 买方/消费者议价能力
- 供应商的议价能力
- 替代品的威胁
- 竞争公司之间的敌对关係
第 5 章市场细分（按价值计算的市场规模：百万美元）
- 按产品分类
- 动脉瘤捲绕和栓塞装置
- 脑球囊血管成形术和支架置入系统
- 神经取栓装置
- 其他设备
- 通过申请
- 缺血性中风
- 脑动脉瘤
- 动静脉畸形/瘘管
- 其他疾病
- 按地区
- 北美
- 美国
- 加拿大
- 墨西哥
- 欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 其他欧洲地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东
- 海湾合作委员会
- 南非
- 其他中东地区
- 南美洲地区
- 巴西
- 阿根廷
- 其他南美洲
- 北美
第六章竞争格局
- 公司简介
- Abbott
- Johnson & Johnson Services, Inc（CERENOVUS）
- Medtronic
- MicroPort Scientific Corporation
- Penumbra, Inc.
- Stryker
- Terumo Corporation
- W. L. Gore & Associates, Inc.
第7章 市场机会今后动向
The neurointerventional devices market is expected to register a CAGR of 7.7% over the forecast period.
The outbreak of COVID-19 affected the neurointerventional devices market in several ways, as it limited the intensive care unit (ICU) beds and ventilation sites owing to the necessity of postponing elective and/or complex cases. Moreover, as per the analysis, there were considerable variations in the management of neuro interventions during and after the pandemic. For instance, as per the report published by Cardiovascular Revascularization Medicine in July 2022, to ascertain the overall effect on vascular intervention trials halted by the COVID-19 pandemic, more research is required in the field of vascular intervention. Hence, the market is expected to rapidly rebound to pre-pandemic levels nonetheless, as a result of the restart of all healthcare facilities, a drop in COVID-19 cases, and follow-up trials on vascular intervention after COVID-19.
The major factors contributing to the growth of the market are the increasing target patient population, ongoing product development and commercialization, and rising research activities in the field of neurovascular therapies.
Neurointerventional devices are used by medical professionals specializing in the domain of the central nervous system (CNS). It is usually done by neuroradiologists, neurosurgeons, and neurologists exploring the endovascular approach to treat the vascular diseases of the central nervous system. The burden of vascular diseases associated with the central nervous system in the target population primarily drives the usage of devices. According to WSO data updated in June 2022, about 12.2 million (12,224,551) people will experience a stroke by the end of the year. In addition, the intracranial aneurysm, also known as a cerebral or brain aneurysm, is a bulging, weakened area in the wall of an artery in the brain. According to data from the National Health Service (NHS), England, updated in April 2022, the prevalence of brain aneurysms could be as high as 1 in 20 people, and brain aneurysms can develop in anyone at any age, but are more common in people over the age of 40. Furthermore, according to updated data from the Brain Aneurysm Foundation in January 2022, an estimated 6.5 million Americans have an unruptured brain aneurysm. About 30,000 people in the United States suffer a brain aneurysm rupture each year. A brain aneurysm ruptures every 18 minutes. The consistently high volume of patients with CNS vascular diseases approaching healthcare facilities is expected to drive the demand for neurointerventional devices.
Similarly, the new device developments and approvals will help the market grow during the study period. For instance, in April 2021, Medtronic received approval from the US FDA for the Pipeline Flex Embolization Device with Shield Technology. The Pipeline Flex Embolization Device diverts blood flow away from a brain aneurysm.
Such factors are altogether contributing to the market's growth over the analysis period. However, the stringent regulations and dearth of skilled neurosurgeons are the primary limitations to the growth of the studied market.
Neurointerventional Devices Market Trends
Ischemic Stroke Segment is Expected to Hold Major Share of the Market Over the Forecast Period
Ischemic stroke is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function. The major factors that positively impact the segment include the increase in the incidence of ischemic stroke and the developments made by various major players in the market.
For instance, as per the WSO's Global Stroke Fact Sheet 2022, there are over 7.6 million new ischemic strokes each year. Globally, over 62% of all incident strokes are ischaemic strokes. This shows a significant rise in cases every year that need proper neurointerventions through neurointerventional devices. Thus, the increase in the incidence of vascular diseases like ischaemic stroke drives the neurointerventional devices market over the forecast period.
Similarly, the recent developments in the devices used for ischemic stroke drove the market growth during the study period. For instance, in June 2022, Rapid Medical enrolled the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) trial to examine the safety and effectiveness of mechanical thrombectomy in distal stroke with TIGERTRIEVER 13, the smallest and most adjustable thrombectomy device. With a wide range of applications linked to arterial-based disease correction, there is significant usage of neurointerventional devices. Similarly, in February 2022, MicroPort NeuroTech Limited (MicroPort NeuroTech) received marketing approval from the NMPA for its self-developed Neurohawk Stent Thrombectomy Device (Neurohawk). The Neurohawk is the clot stent retriever launched by MicroPort NeuroTech for acute ischemic stroke treatment.
Thus, given the above-mentioned facts, the studied market is expected to grow over the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
The United States contributes the most to the North American region and is responsible for the dominance of the region across the world. North America, with its advanced healthcare infrastructure across the majority of places and the presence of many medical device companies well-connected with hospitals, primarily boosts the growth of this market.
According to the statistics published by the CDC in April 2022, more than 795,000 Americans have strokes. Each year, 610,000 of these instances are discovered to be new. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked. Hence, the increase in stroke cases in the region increases the demand for neurointerventional devices for proper management, which helps in the growth of the market during the forecast period.
Furthermore, new device approvals and launches also help the market grow. For instance, in February 2022, CERENOVUS launched EMBOGUARD, a next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke. The EMBOGUARD balloon guide catheter is designed to optimize the removal of clots by controlling blood flow locally during MT procedures. Thus, all the new device approvals and launches help the market grow in the region.
Thus, all the aforementioned factors are expected to boost the market's growth over the forecast period.
Neurointerventional Devices Market Competitor Analysis
The neurointerventional devices market is moderately competitive and consists of several major players. The companies have identified consistent growth opportunities in the treatment of endovascular-based diseases via neurointerventional devices. Some of the major companies in this segment include Abbott, Johnson & Johnson Services, Inc. (CERENOVUS), Medtronic, Stryker, Penumbra, Inc., MicroPort Scientific Corporation, Terumo Corporation, and W. L. Gore & Associates, Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions & Market Defination
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Target Patient Population
- 4.2.2 Ongoing Product Development and Commercialization
- 4.2.3 Rising Research Activities in the Field of Neurovascular Therapies
- 4.3 Market Restraints
- 4.3.1 Stringent Regulations
- 4.3.2 Dearth of Skilled Neurosurgeons
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - by USD million)
- 5.1 By Product
- 5.1.1 Aneurysm Coiling & Embolization Devices
- 5.1.2 Cerebral Balloon Angioplasty and Stenting Systems
- 5.1.3 Neurothrombectomy Devices
- 5.1.4 Other Devices
- 5.2 By Application
- 5.2.1 Ischemic Stroke
- 5.2.2 Cerebral Aneurysms
- 5.2.3 Arteriovenous Malformation and Fistulas
- 5.2.4 Other Diseases
- 5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
- 5.3.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Abbott
- 6.1.2 Johnson & Johnson Services, Inc (CERENOVUS)
- 6.1.3 Medtronic
- 6.1.4 MicroPort Scientific Corporation
- 6.1.5 Penumbra, Inc.
- 6.1.6 Stryker
- 6.1.7 Terumo Corporation
- 6.1.8 W. L. Gore & Associates, Inc.
